Genvec Inc.

Genvec Inc.

Genvec Inc.

Overview
Date Founded

1992

Headquarters

65 West Watkins Mill Road,Gaithersburg, MD 20878

Type of Company

Private

Employees (Worldwide)

15

Industries

Pharmaceuticals
Biotechnology

Company Description

GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). GenVec, Inc. is based in Gaithersburg, Maryland.

Contact Data
Trying to get in touch with decision makers at Genvec Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Treasurer

Vice President & Secretary

Owner Partner

Chief Sales Officer

Associate Director

Purchasing Manager

Engineering Design

Board of Directors

Chief Legal Officer at Precigen, Inc.

Senior Vice President-Intellectual Property Affairs at Precigen, Inc.

Paths to Genvec Inc.
Potential Connections via
Relationship Science
You
Genvec Inc.
Recent Transactions
Details Hidden

Precigen, Inc. purchases Genvec Inc.

Details Hidden

Genvec Inc. raised money in a private placement transaction

Details Hidden

Mytogen, Inc. purchases Genvec, Inc. /Myoblast Cell Therapy Ops from Genvec Inc.

Transaction Advisors
Accountant

Advised onGenvec Inc. purchases Diacrin, Inc. (Delaware)

Investment Advisor

Advised onGenvec Inc. purchases Diacrin, Inc. (Delaware)

Underwriter

Advised onGenvec Inc. issued USD Common Stock

Legal Advisor

Advised onPrecigen, Inc. purchases Genvec Inc.

Legal Advisor

Advised onGenvec Inc. issued USD Common Stock

Legal Advisor

Advised onPrecigen, Inc. purchases Genvec Inc.

Advisors & Consultants
Legal Advisor

Partner at Arnold & Porter LLP

Legal Advisor

Partner at Hogan & Lovells LLP

Legal Advisor

Attorney at Arnold & Porter LLP

Clients

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

The Government of the United States of America is the federal government of the republic of fifty states that constitute the United States, as well as one capital district, and several other territories. The federal government is composed of three distinct branches: legislative, executive and judicial, whose powers are vested by the U.S. Constitution in the Congress, the President, and the federal courts, including the Supreme Court, respectively.

C.H. Boehringer Sohn AG & Co. KG is a holding company, with interests in the manufacturing of pharmaceutical products. It offers prescription drugs for the treatment of human respiratory, cardiovascular, gastrointestinal, and central nervous system diseases, including human immunodeficiency virus (HIV) infection and cancer. The company was founded on April 4, 1894 and is headquartered in Ingelheim am Rhein, Germany.

Key Stats and Financials As of
Market Capitalization
$14.6M
Total Enterprise Value
Earnings Per Share
Non-Profit Donations & Grants
$1 - $2,499
2013
$1 - $2,499
2009
$5,000 - $10K
2008
Investors
Details Hidden

Chairman-Genetic Medicine at Cornell University - Weill Cornell Medical College

Details Hidden

Canaan Management focuses on investments primarily in the technology and healthcare sectors. In the technology sector, the firm focuses on digital media, communications, mobility, enterprise software and clean technology. Within the healthcare sector, Canaan Partners focuses on investments in biopharmaceuticals, medical devices and diagnostics. Canaan Partners also invests technology-based Indian companies in the following sectors: consumer Internet, digital media, mobile and enterprise and managed services. In Israel, the firm seeks to invest in the development of early-stage companies in the following areas: (1) consumer Internet and digital media (2) communications infrastructure (3) enterprise software (4) clean technology and (5) medical device technologies.

Suppliers
Lonza Group AG Pharmaceuticals | Basel, Che

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate. The Pharma & Biotech segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems. The Specialty Ingredients segment consists of two divisions, consumer health and consumer resources and protection. The Corporate segment includes corporate functions, such as finance and accounting, legal, communication, information technology, and human resources. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Cornell University Computer Software | Ithaca, New York

Cornell is a privately endowed research university and a partner of the State University of New York. As the federal land-grant institution in New York State, they have a responsibility—unique within the Ivy League—to make contributions in all fields of knowledge in a manner that prioritizes public engagement to help improve the quality of life in our state, the nation, the world.

Baylor College of Medicine Schools & Student Services | Houston, Texas

Baylor College of Medicine is a health sciences university that creates knowledge and applies science and discoveries to further education, healthcare and community service locally and globally.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Alnylam Pharmaceuticals, Inc. Pharmaceuticals - Cambridge, Massachusetts

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Genvec Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Genvec Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Genvec Inc..